Fate Therapeutics Announces Pricing of Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Fate Therapeutics (FATE) PT Raised to $40 at Oppenheimer
June 10, 2020 8:16 AM EDTOppenheimer analyst Matthew Biegler raised the price target on Fate Therapeutics (NASDAQ: FATE) to $40.00 (from $34.00) while maintaining a Outperform rating following the company's update on its iPSC-derived cell therapy programs in conjunction with an equity financing. The update included preliminary data from the first... More
Fate Therapeutics (FATE) PT Raised to $45 at Guggenheim
June 10, 2020 7:51 AM EDTGuggenheim analyst Michael Schmidt raised the price target on Fate Therapeutics (NASDAQ: FATE) to $45.00 (from $43.00) while maintaining a Buy rating after the company provided a portfolio-wide clinical update. The update was part of the SEC filings for FATE's capital raise.
Guggenheim... More
